Immunogenicity of an HPV-16 L2 DNA vaccine
Inga I. Hitzeroth(University of Cape Town), W. Martin Kast(University of Southern California), Jo‐Ann S. Passmore(National Health Laboratory Service), Edward P. Rybicki(University of Cape Town), Debbie Stewart(Wellcome Centre for Infectious Diseases Research in Africa), Anna‐Lise Williamson(University of Cape Town), Enid Shephard(University of Cape Town), Martin Müller(Klinikum Region Hannover)
Cited by 27
Related Papers
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
|Nature Medicine|2002|549
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
|The Journal of Immunology|2001|533